文献速递急性肾损伤肾小球疾病

肾脏组织病理学可预测接受血浆置换治疗的ANCA相关性血管炎合并急性肾损伤患者的肾功能

Kidney Histopathology Can Predict Kidney Function in ANCA-Associated Vasculitides with Acute Kidney Injury Treated with Plasma Exchanges.
PubMed 文献 · J Am Soc Nephrol · 2022-01-24

多中心回顾性研究纳入188例接受血浆置换(PLEX)和237例未接受PLEX的ANCA相关性血管炎合并急性肾损伤患者,主要结局为12个月死亡或肾脏替代治疗(KRT)。全人群未见PLEX显著获益,但预测模型识别出PLEX推荐组(177例预测概率提升>5%),该组12个月死亡或KRT风险差显著低于非推荐组(-15.9% vs -4.8%)。作者结论强调PLEX在全人群未改善主要结局,但识别出可能获益的亚组,需验证后方可用于临床决策。

要点

  • 全研究人群中PLEX与主要结局(12个月死亡或KRT)无显著获益。
  • 预测模型识别PLEX推荐组177例,其12个月死亡或KRT风险差显著低于非推荐组(-15.9% vs -4.8%)。
  • PLEX推荐组中显微镜下多血管炎、MPO-ANCA、更高血清肌酐、新月体及硬化类、更高Brix评分更常见。

核心结论

  • PLEX在全研究人群中未与更好的主要结局相关,但识别出可能从PLEX获益的亚组患者。
  • 这些发现须在用于临床决策前得到验证。

研究设计与样本

  • 多中心回顾性研究,纳入188例接受PLEX和237例未接受PLEX的ANCA相关性血管炎合并急性肾损伤患者。
  • 主要结局为12个月时死亡或KRT。

主要发现

  • 全研究人群中PLEX对主要结局无显著获益。
  • 预测模型显示223例患者接受PLEX的预测结局优于未接受PLEX,其中177例接受PLEX相比未接受PLEX在12个月时存活且免于KRT的预测概率增加>5%,定义为PLEX推荐组。
  • PLEX推荐组12个月死亡或KRT的风险差显著低于PLEX非推荐组(-15.9%;95% CI,-29.4至-2.5 vs -4.8%;95% CI,14.9至5.3)。
  • PLEX推荐组中显微镜下多血管炎、MPO-ANCA、更高血清肌酐、新月体及硬化类、更高Brix评分更常见。
  • 一个易于使用的评分识别了可能从PLEX获益的患者。

关键数值与推荐

  • PLEX推荐组定义:接受PLEX相比未接受PLEX在12个月时存活且免于KRT的预测概率增加>5%。
  • PLEX推荐组12个月死亡或KRT风险差为-15.9%(95% CI,-29.4至-2.5),PLEX非推荐组为-4.8%(95% CI,14.9至5.3)。

临床怎么用

  • 原文未据此给出推荐;作者指出这些发现须在用于临床决策前得到验证。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data from the PEXIVAS trial challenged the role of plasma exchange (PLEX) in ANCA-associated vasculitides (AAV). We aimed to describe kidney biopsy from patients with AAV treated with PLEX, evaluate whether histopathologic findings could predict kidney function, and identify which patients would most benefit from PLEX. METHODS: We performed a multicenter, retrospective study on 188 patients with AAV and AKI treated with PLEX and 237 not treated with PLEX. The primary outcome was mortality or KRT at 12 months (M12). RESULTS: No significant benefit of PLEX for the primary outcome was found. To identify patients benefitting from PLEX, we developed a model predicting the average treatment effect of PLEX for an individual depending on covariables. Using the prediction model, 223 patients had a better predicted outcome with PLEX than without PLEX, and 177 of them had >5% increased predicted probability with PLEX compared with without PLEX of being alive and free from KRT at M12, which defined the PLEX-recommended group. Risk difference for death or KRT at M12 was significantly lower with PLEX in the PLEX-recommended group (-15.9%; 95% CI, -29.4 to -2.5) compared with the PLEX not recommended group (-4.8%; 95% CI, 14.9 to 5.3). Microscopic polyangiitis, MPO-ANCA, higher serum creatinine, crescentic and sclerotic classes, and higher Brix score were more frequent in the PLEX-recommended group. An easy to use score identified patients who would benefit from PLEX. The average treatment effect of PLEX for those with recommended treatment corresponded to an absolute risk reduction for death or KRT at M12 of 24.6%. CONCLUSIONS: PLEX was not associated with a better primary outcome in the whole study population, but we identified a subset of patients who could benefit from PLEX. However, these findings must be validated before utilized in clinical decision making.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Nezam D, Porcher R, Grolleau F, et al. Kidney Histopathology Can Predict Kidney Function in ANCA-Associated Vasculitides with Acute Kidney Injury Treated with Plasma Exchanges. J Am Soc Nephrol. 2022. PMID: 35074934. doi:10.1681/ASN.2021060771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。